These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 33905667)

  • 1. Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy.
    Bronte G; Cafaro A; Pasini L; Priano I; Andrikou K; Cravero P; Burgio MA; Delmonte A; Crinò L
    Expert Rev Anticancer Ther; 2021 Aug; 21(8):809-817. PubMed ID: 33905667
    [No Abstract]   [Full Text] [Related]  

  • 2. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
    Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
    Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world treatment duration in ALK-positive non-small-cell lung cancer patients receiving brigatinib through the early access program.
    Lin HM; Pan X; Hou P; Allen S; Baumann P; Hochmair MJ
    Future Oncol; 2020 May; 16(15):1031-1041. PubMed ID: 32338548
    [No Abstract]   [Full Text] [Related]  

  • 5. Indirect comparisons of brigatinib and alectinib for front-line
    Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Walton LJ; Kay S; Cichewicz A; Neupane B; Fahrbach K; Popat S; Camidge DR
    Future Oncol; 2022 Jun; 18(20):2499-2510. PubMed ID: 35608148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
    Descourt R; Perol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cortot A; Guisier F; Galland L; Dô P; Schott R; Dansin E; Arrondeau J; Auliac JB; Chouaid C
    Lung Cancer; 2019 Oct; 136():109-114. PubMed ID: 31491676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
    Cranmer H; Kearns I; Young M; Humphries MJ; Trueman D
    J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099
    [No Abstract]   [Full Text] [Related]  

  • 8. Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3).
    Popat S; Liu G; Lu S; Song G; Ma X; Yang JC
    Future Oncol; 2021 Nov; 17(32):4237-4247. PubMed ID: 34423676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).
    Ou SI; Nishio M; Ahn MJ; Mok T; Barlesi F; Zhou C; Felip E; de Marinis F; Kim SW; Pérol M; Liu G; Migliorino MR; Kim DW; Novello S; Bearz A; Garrido P; Mazieres J; Morabito A; Lin HM; Yang H; Niu H; Zhang P; Kim ES
    J Thorac Oncol; 2022 Dec; 17(12):1404-1414. PubMed ID: 36096442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.
    Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; García Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira A; Gettinger SN; Tiseo M; Lin HM; Gupta N; Hanley MJ; Ni Q; Zhang P; Popat S
    J Clin Oncol; 2020 Nov; 38(31):3592-3603. PubMed ID: 32780660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of brigatinib as a promising treatment option for non-small cell lung cancer.
    Hamilton G; Hochmair MJ
    Expert Opin Pharmacother; 2019 Sep; 20(13):1551-1561. PubMed ID: 31328968
    [No Abstract]   [Full Text] [Related]  

  • 12. Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
    Camidge DR; Kim HR; Ahn MJ; Yang JCH; Han JY; Hochmair MJ; Lee KH; Delmonte A; Garcia Campelo MR; Kim DW; Griesinger F; Felip E; Califano R; Spira AI; Gettinger SN; Tiseo M; Lin HM; Liu Y; Vranceanu F; Niu H; Zhang P; Popat S
    J Thorac Oncol; 2021 Dec; 16(12):2091-2108. PubMed ID: 34537440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
    Camidge DR; Kim HR; Ahn MJ; Yang JC; Han JY; Lee JS; Hochmair MJ; Li JY; Chang GC; Lee KH; Gridelli C; Delmonte A; Garcia Campelo R; Kim DW; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger SN; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S
    N Engl J Med; 2018 Nov; 379(21):2027-2039. PubMed ID: 30280657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer.
    Umbela S; Ghacha S; Matuknauth R; Gause S; Joshee S; Deshmukh RR
    Curr Probl Cancer; 2019 Dec; 43(6):100477. PubMed ID: 31109722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upfront Management of ALK-Rearranged Metastatic Non-small Cell Lung Cancer: One Inhibitor Fits All?
    Tabbò F; Passiglia F; Novello S
    Curr Oncol Rep; 2021 Jan; 23(1):10. PubMed ID: 33387080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases.
    Naito T; Shiraishi H; Fujiwara Y
    Jpn J Clin Oncol; 2021 Jan; 51(1):37-44. PubMed ID: 33147606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial.
    Yang JC; Liu G; Lu S; He J; Burotto M; Ahn MJ; Kim DW; Liu X; Zhao Y; Vincent S; Yin J; Ma X; Lin HM; Popat S
    J Thorac Oncol; 2023 Dec; 18(12):1743-1755. PubMed ID: 37574132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall survival indirect treatment comparison between brigatinib and alectinib for the treatment of front-line anaplastic lymphoma kinase-positive non-small cell lung cancer using data from ALEX and final results from ALTA-1L.
    Reckamp KL; Lin HM; Cranmer H; Wu Y; Zhang P; Kay S; Walton LJ; Shen J; Popat S; Camidge DR
    Curr Med Res Opin; 2022 Sep; 38(9):1587-1593. PubMed ID: 35815801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?
    Maione P; Palma V; Pucillo G; Gridelli C
    Expert Opin Ther Targets; 2024 Aug; 28(8):659-668. PubMed ID: 39160676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
    Ma HC; Liu YH; Ding KL; Liu YF; Zhao WJ; Zhu YJ; Chang XS; Chen YD; Xiao ZZ; Yu YY; Zhou R; Zhang HB
    BMC Cancer; 2021 Nov; 21(1):1278. PubMed ID: 34836510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.